Skip to main content
Top
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Myasthenia Gravis | Research

Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study

Authors: Hannah Wilcke, Stefanie Glaubitz, Fabian Kück, Christoph Anten, David Liebetanz, Jens Schmidt, Jana Zschüntzsch

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Myasthenia gravis (MG) affects individuals as a chronic autoimmune disease for many years. Commonly, chronic diseases significantly reduce the patients’ quality of life. Aiming to improve the future quality of life in MG, this study assessed the factors impacting quality of life. As gender-specific medicine is becoming increasingly important, this study also focused on understanding gender differences in the outcome of MG.

Methods

The study is a combined monocentric, retrospective and prospective database analysis of patient records based on 2,370 presentations of 165 patients with clinically, serologically and/or electrophysiologically confirmed MG over an observation period of up to 47 years. The data collection included the following parameters: antibody status, disease severity, age, medication use, gender, and disease duration. In addition, a prospective survey was conducted on the quality of life using the Myasthenia gravis-specific 15-item Quality of Life scale (MG-QoL15) and on the activities of daily living using the MG-specific Activities of Daily Living scale (MG-ADL).

Results

Of the 165 patients, 85 were male (51.5%) and 80 were female (48.5%). The remaining baseline characteristics (e.g. age and antibody status) were consistent with other myasthenia gravis cohorts. A high body mass index (BMI) (p = 0.005) and a high disease severity (p < 0.001) were significantly associated with lower disease-specific quality of life. Additionally, the quality of life in women with MG was significantly reduced compared to male patients (19.7 vs. 13.0 points in the MG-QoL15, p = 0.024). Gender differences were also observable in terms of the period between initial manifestation and initial diagnosis and women were significantly more impaired in their activities of daily living (MG-ADL) than men (4.8 vs. 3.0 points, p = 0.032).

Conclusion

Women with MG had significantly poorer disease specific quality of life compared to men as well as patients with a higher BMI. In order to improve the quality of life, gender-specific medicine and further investigation regarding a modification of the quality of life by lowering the BMI are essential and necessary.

Trial registration

Study approval by the Ethics Committee of the University Medical Center Göttingen was granted (number 6/5/18).
Literature
1.
2.
go back to reference Hellmann MA, Mosberg-Galili R, Steiner I. Myasthenia gravis in the elderly. J Neurol Sci. 2013;325(1–2):1–5.PubMedCrossRef Hellmann MA, Mosberg-Galili R, Steiner I. Myasthenia gravis in the elderly. J Neurol Sci. 2013;325(1–2):1–5.PubMedCrossRef
3.
go back to reference Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain J Neurol. 1980;103(3):579–601.CrossRef Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain J Neurol. 1980;103(3):579–601.CrossRef
4.
go back to reference Aarli JA, Romi F, Skeie GO, Gilhus NE. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci. 2003;998:424–31.PubMedCrossRef Aarli JA, Romi F, Skeie GO, Gilhus NE. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci. 2003;998:424–31.PubMedCrossRef
7.
go back to reference Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974;186(4158):55–7.PubMedCrossRef Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974;186(4158):55–7.PubMedCrossRef
8.
go back to reference Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016;263(8):1473–94.PubMedPubMedCentralCrossRef Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016;263(8):1473–94.PubMedPubMedCentralCrossRef
9.
go back to reference Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014;82(22):1976–83.PubMedCrossRef Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014;82(22):1976–83.PubMedCrossRef
10.
go back to reference Cordts I, Bodart N, Hartmann K, Karagiorgou K, Tzartos JS, Mei L, et al. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. J Neurol. 2017;264(6):1193–203.PubMedCrossRef Cordts I, Bodart N, Hartmann K, Karagiorgou K, Tzartos JS, Mei L, et al. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. J Neurol. 2017;264(6):1193–203.PubMedCrossRef
12.
go back to reference Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;2005(2):CD002828.PubMedPubMedCentral Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;2005(2):CD002828.PubMedPubMedCentral
13.
go back to reference Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59–62.PubMedCrossRef Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59–62.PubMedCrossRef
15.
go back to reference Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;2002(4):CD002275.PubMedPubMedCentral Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;2002(4):CD002275.PubMedPubMedCentral
16.
go back to reference Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–22.PubMedPubMedCentralCrossRef Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–22.PubMedPubMedCentralCrossRef
17.
go back to reference Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020;33(5):545–52.PubMedCrossRef Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020;33(5):545–52.PubMedCrossRef
18.
go back to reference Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691–701.PubMedCrossRef Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691–701.PubMedCrossRef
20.
go back to reference Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86.PubMedCrossRef Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86.PubMedCrossRef
22.
go back to reference Howard JF, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–73.PubMedPubMedCentralCrossRef Howard JF, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–73.PubMedPubMedCentralCrossRef
24.
go back to reference Bullinger M. [Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine]. Psychother Psychosom Med Psychol. 1997;47(3–4):76–91.PubMed Bullinger M. [Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine]. Psychother Psychosom Med Psychol. 1997;47(3–4):76–91.PubMed
25.
go back to reference Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957–63.PubMedCrossRef Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957–63.PubMedCrossRef
26.
27.
go back to reference Martínez-Lapiscina EH, Erro ME, Ayuso T, Jericó I. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve. 2012;46(2):174–80.PubMedCrossRef Martínez-Lapiscina EH, Erro ME, Ayuso T, Jericó I. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve. 2012;46(2):174–80.PubMedCrossRef
28.
go back to reference Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016;6(10):e00538.PubMedPubMedCentralCrossRef Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016;6(10):e00538.PubMedPubMedCentralCrossRef
29.
go back to reference Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, et al. Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment. Muscle Nerve. 2019;60(6):707–15.PubMedPubMedCentralCrossRef Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, et al. Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment. Muscle Nerve. 2019;60(6):707–15.PubMedPubMedCentralCrossRef
30.
go back to reference Fitzthum K. Lebensqualität bei myasthenia gravis. Klinische einflussfaktoren und langfristiger verlauf. Berlin, Germany: Charité - Universitätsmedizin Berlin; 2015. Fitzthum K. Lebensqualität bei myasthenia gravis. Klinische einflussfaktoren und langfristiger verlauf. Berlin, Germany: Charité - Universitätsmedizin Berlin; 2015.
31.
go back to reference Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769–72.PubMedCrossRef Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769–72.PubMedCrossRef
35.
go back to reference Therneau TM. A Package for survival analysis in S; 2015. Therneau TM. A Package for survival analysis in S; 2015.
36.
go back to reference Murphy N, Confavreux C, Haas J, König N, Roullet E, Sailer M, et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of multiple sclerosis study group. J Neurol Neurosurg Psychiatry. 1998;65(4):460–6.PubMedPubMedCentralCrossRef Murphy N, Confavreux C, Haas J, König N, Roullet E, Sailer M, et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of multiple sclerosis study group. J Neurol Neurosurg Psychiatry. 1998;65(4):460–6.PubMedPubMedCentralCrossRef
37.
38.
go back to reference Nelson ND, Trail M, Van JN, Appel SH, Lai EC. Quality of life in patients with amyotrophic lateral sclerosis: perceptions, coping resources, and illness characteristics. J Palliat Med. 2003;6(3):417–24.PubMedCrossRef Nelson ND, Trail M, Van JN, Appel SH, Lai EC. Quality of life in patients with amyotrophic lateral sclerosis: perceptions, coping resources, and illness characteristics. J Palliat Med. 2003;6(3):417–24.PubMedCrossRef
39.
go back to reference Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schröder R, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(9):1473–81.PubMedCrossRef Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schröder R, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(9):1473–81.PubMedCrossRef
40.
go back to reference Lipka AF, Boldingh MI, van Zwet EW, Schreurs MWJ, Kuks JBM, Tallaksen CM, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020;94(5):e511–20.PubMedPubMedCentralCrossRef Lipka AF, Boldingh MI, van Zwet EW, Schreurs MWJ, Kuks JBM, Tallaksen CM, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020;94(5):e511–20.PubMedPubMedCentralCrossRef
41.
go back to reference Basta IZ, Pekmezović TD, Perić SZ, Kisić-Tepavčević DB, Rakočević-Stojanović VM, Stević ZD, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2012;33(6):1375–81. Basta IZ, Pekmezović TD, Perić SZ, Kisić-Tepavčević DB, Rakočević-Stojanović VM, Stević ZD, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2012;33(6):1375–81.
42.
go back to reference Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012;46(2):166–73.PubMedCrossRef Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012;46(2):166–73.PubMedCrossRef
43.
go back to reference Mourão AM, Gomez RS, Barbosa LSM, Freitas DdaS, Comini-Frota ER, Kummer A, et al. Determinants of quality of life in Brazilian patients with myasthenia gravis. Clin Sao Paulo Braz. 2016;71(7):370–4.CrossRef Mourão AM, Gomez RS, Barbosa LSM, Freitas DdaS, Comini-Frota ER, Kummer A, et al. Determinants of quality of life in Brazilian patients with myasthenia gravis. Clin Sao Paulo Braz. 2016;71(7):370–4.CrossRef
44.
go back to reference Dong D, Chong MKC, Wu Y, Kaminski H, Cutter G, Xu X, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18(1):296.PubMedPubMedCentralCrossRef Dong D, Chong MKC, Wu Y, Kaminski H, Cutter G, Xu X, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18(1):296.PubMedPubMedCentralCrossRef
45.
go back to reference Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C. Patient-acceptable symptom states in myasthenia gravis. Neurology. 2020;95(12):e1617–28.PubMedCrossRef Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C. Patient-acceptable symptom states in myasthenia gravis. Neurology. 2020;95(12):e1617–28.PubMedCrossRef
46.
go back to reference Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11:553626.PubMedPubMedCentralCrossRef Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11:553626.PubMedPubMedCentralCrossRef
47.
go back to reference Diez Porras L, Homedes C, Alberti MA, Velez Santamaria V, Casasnovas C. Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales. J Clin Med. 2022;11(8):2189.PubMedPubMedCentralCrossRef Diez Porras L, Homedes C, Alberti MA, Velez Santamaria V, Casasnovas C. Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales. J Clin Med. 2022;11(8):2189.PubMedPubMedCentralCrossRef
48.
go back to reference Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient’s perspective. J Neurol. 2022;269(6):3050–63.PubMedCrossRef Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient’s perspective. J Neurol. 2022;269(6):3050–63.PubMedCrossRef
49.
go back to reference Braz NFT, Rocha NP, Vieira ÉLM, Gomez RS, Kakehasi AM, Teixeira AL. Body composition and adipokines plasma levels in patients with myasthenia gravis treated with high cumulative glucocorticoid dose. J Neurol Sci. 2017;381:169–75.PubMedCrossRef Braz NFT, Rocha NP, Vieira ÉLM, Gomez RS, Kakehasi AM, Teixeira AL. Body composition and adipokines plasma levels in patients with myasthenia gravis treated with high cumulative glucocorticoid dose. J Neurol Sci. 2017;381:169–75.PubMedCrossRef
51.
go back to reference Mensink GBM, Schienkiewitz A, Haftenberger M, Lampert T, Ziese T, Scheidt-Nave C. Übergewicht und adipositas in Deutschland: ergebnisse der studie zur gesundheit erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2013;56(5–6):786–94. https://doi.org/10.1007/s00103-012-1656-3 Mensink GBM, Schienkiewitz A, Haftenberger M, Lampert T, Ziese T, Scheidt-Nave C. Übergewicht und adipositas in Deutschland: ergebnisse der studie zur gesundheit erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2013;56(5–6):786–94. https://​doi.​org/​10.​1007/​s00103-012-1656-3
52.
go back to reference Lee I, Kaminski HJ, Xin H, Cutter G. Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry: gender and QOL in MG patients. Muscle Nerve. 2018;58(1):90–8. https://doi.org/10.1002/mus.26104 Lee I, Kaminski HJ, Xin H, Cutter G. Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry: gender and QOL in MG patients. Muscle Nerve. 2018;58(1):90–8. https://​doi.​org/​10.​1002/​mus.​26104
53.
go back to reference Thomsen JLS, Vinge L, Harbo T, Andersen H. Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study. Muscle Nerve. 2021;64(5):538–44.PubMedCrossRef Thomsen JLS, Vinge L, Harbo T, Andersen H. Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study. Muscle Nerve. 2021;64(5):538–44.PubMedCrossRef
54.
go back to reference Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primer. 2019;5(1):30.CrossRef Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primer. 2019;5(1):30.CrossRef
55.
go back to reference Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekjær H, Verschuuren JJGM, Tallaksen CME. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology. 2016;87(20):2139–45.PubMedPubMedCentralCrossRef Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekjær H, Verschuuren JJGM, Tallaksen CME. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology. 2016;87(20):2139–45.PubMedPubMedCentralCrossRef
56.
go back to reference Stickler DE, Stickler LL. Single-fiber electromyography during menstrual exacerbation and ovulatory suppression in MuSK antibody-positive myasthenia gravis. Muscle Nerve. 2007;35(6):808–11.PubMedCrossRef Stickler DE, Stickler LL. Single-fiber electromyography during menstrual exacerbation and ovulatory suppression in MuSK antibody-positive myasthenia gravis. Muscle Nerve. 2007;35(6):808–11.PubMedCrossRef
57.
go back to reference Lee I, Kaminski HJ, McPherson T, Feese M, Cutter G. Gender differences in prednisone adverse effects: survey result from the MG registry. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e507.PubMedPubMedCentralCrossRef Lee I, Kaminski HJ, McPherson T, Feese M, Cutter G. Gender differences in prednisone adverse effects: survey result from the MG registry. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e507.PubMedPubMedCentralCrossRef
58.
go back to reference Wiendl H. Meisel A. Diagnostik und therapie myasthener syndrome, S2k-Leitlinie. DGN; 2022. Wiendl H. Meisel A. Diagnostik und therapie myasthener syndrome, S2k-Leitlinie. DGN; 2022.
60.
go back to reference Nixon AE, Chen J, Sexton DJ, Muruganandam A, Bitonti AJ, Dumont J, et al. Fully human monoclonal antibody inhibitors of the neonatal FC receptor reduce circulating IgG in non-human primates. Front Immunol. 2015;6:176.PubMedPubMedCentralCrossRef Nixon AE, Chen J, Sexton DJ, Muruganandam A, Bitonti AJ, Dumont J, et al. Fully human monoclonal antibody inhibitors of the neonatal FC receptor reduce circulating IgG in non-human primates. Front Immunol. 2015;6:176.PubMedPubMedCentralCrossRef
Metadata
Title
Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study
Authors
Hannah Wilcke
Stefanie Glaubitz
Fabian Kück
Christoph Anten
David Liebetanz
Jens Schmidt
Jana Zschüntzsch
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03406-0

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue